Landiolol, an ultra-short-acting β1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis

Table 1 Patients’ characteristics

	Landiolol	Control
n	39	22
Age, yr	70.7 ± 12.3	70.8 ± 12.5
Underlying disease
Cardiovascular disease	16 (41.0%)	11 (50.0%)
Malignancy	11 (28.2%)	3 (13.6%)
Immunological disorder	3 (7.7%)	2 (9.1%)
Others	9 (23.1%)	6 (27.2%)
Infected site
Respiratory tract	17 (43.6%)	14 (63.6%)
Intra-abdominal	13 (33.3%)a	2 (9.1%)
Blood	5 (12.8%)	0 (0%)
Skin/soft tissue	2 (5.1%)	0 (0%)
Urinary tract	1 (2.6%)a	4 (18.2%)
Others	1 (2.6%)	2 (9.1%)
APACHE II	22.8 ± 5.4	22.1 ± 7.7
SOFA	8.8 ± 4.0	9.1 ± 3.9

^aP < 0.05 vs control. APACHE II: Acute Physiology and Chronic Health Evaluation II; SOFA: Sequential Organ Failure Assessment.

Table 2 Hemodynamics

	Landiolol	Control
Heart rate, bpm	145 ± 14a	136 ± 21
Systolic arterial pressure, mmHg	113 ± 34a	137 ± 39
Diastolic arterial pressure, mmHg	60 ± 17	66 ± 13
Mean arterial pressure, mmHg	78 ± 21	86 ± 28
Diastolic pulmonary arterial pressure, mmHg	19 ± 6	20 ± 7
Cardiac output, L/min	3.9 ± 1.7	5.8 ± 1.5
Cardiac index, L/min per square meter	2.5 ± 1.1a	4.0 ± 1.3
SVRI, dyne∙s/m5 per square meter	2068 ± 795	1615 ± 399
Arrhythmia
Paroxysmal atrial fibrillation/flutter	34 (87%)	13 (60%)
Paroxysmal atrial tachycardia	4 (10%)	8 (36%)
Paroxysmal supraventricular tachycardia	1 (3%)	1 (5%)
Concomitant drugs to control arrhythmia
Calcium-channel blocker	3 (8%)	5 (22%)
Other β blockers	0 (0%)	3 (14%)
Disopyramid phosphate	0 (0%)	1 (5%)
Amiodarone	0 (0%)	1 (5%)

^aP < 0.05 vs control. SVRI: Systemic vascular resistance index.